Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells

Yixiang Han, Yuqing Dong, Qianqian Yang, Wanling Xu, Songfu Jiang, Zhijie Yu, Yu Kang, Shenghui ZhangFrontiers in Immunology 2018 · DOI

TL;DR

Acute Myeloid Leukemia (AML) cells express ICOSL, a molecule that promotes the expansion of regulatory T cells (Tregs). These expanded Tregs, in turn, secrete IL-10, which fuels AML cell proliferation. Blocking ICOSL signaling in a mouse model reduced Treg generation and slowed AML progression, suggesting ICOSL and ICOS+ Tregs as potential therapeutic targets and prognostic markers.

What Problem Does This Paper Address?

Acute Myeloid Leukemia (AML) is a complex blood cancer where immature myeloid cells accumulate. While the role of the tumor microenvironment in AML progression is recognized, the specific mechanisms by which tumor cells influence immune cells, particularly regulatory T cells (Tregs), remain unclear. Tregs are crucial for maintaining immune homeostasis but can also suppress anti-tumor immunity, and their accumulation in AML is linked to poorer outcomes. This paper investigates how AML cells themselves contribute to the expansion of these immunosuppressive Tregs.

Methods

The researchers employed a multi-pronged approach:

  • Cell Culture and Co-culture: They cultured AML cell lines and primary AML cells with CD4+ T cells to observe interactions and Treg induction.
  • Flow Cytometry: This was a central technique used to identify and quantify specific cell populations (e.g., CD4+, CD25+, Foxp3+, ICOS+) and measure protein expression on cell surfaces and intracellularly.
  • Quantitative RT-PCR: Used to measure mRNA expression levels of ICOSL in different cell types.
  • Cytokine Analysis (ELISA): Employed to quantify levels of IL-10 and TNF-α in plasma and cell culture supernatants.
  • Western Blot: Utilized to assess the activation of key signaling pathways (Akt, Erk1/2, p38, Stat3) in response to IL-10 stimulation.
  • Animal Models: A murine model of AML (using C1498 cells) was established to study the in vivo effects of ICOSL blockade.
  • Immunohistochemistry: Used to examine tissue morphology in the mouse model.
  • Statistical Analysis: Standard statistical methods (t-tests, ANOVA) were used to compare groups and determine significance.

Datasets

The study utilized:

  • Patient Samples: Bone marrow and peripheral blood samples from 121 newly diagnosed adult AML patients (excluding APL) and 40 healthy donors.
  • AML Cell Lines: HL-60, HEL, THP-1, and U937 human AML cell lines, and the murine C1498 AML cell line.

No new benchmarks were introduced; the focus was on analyzing existing biological samples and established cell lines.

Key Insights and Ideas

  • AML Cells as Treg Inducers: The study reveals that AML cells actively promote the expansion of Tregs by expressing ICOSL. This is a direct mechanism by which the tumor manipulates the immune system to its advantage.
  • ICOS/ICOSL Axis in Treg Expansion: The interaction between ICOSL on AML cells and ICOS on T cells is critical for inducing and maintaining Treg markers (Foxp3 and CD25) and promoting their suppressive function.
  • TNF-α as a Regulator of ICOSL: Pro-inflammatory cytokine TNF-α, often found in the tumor microenvironment, significantly upregulates ICOSL expression on AML cells, suggesting a feedback loop that enhances Treg induction.
  • ICOS+ Tregs: A Potent Subpopulation: A specific subset of Tregs expressing both ICOS and Foxp3 (ICOS+ Tregs) were found to be particularly effective at secreting IL-10.
  • IL-10 Fuels AML Proliferation: The IL-10 secreted by ICOS+ Tregs doesn't just suppress other immune cells; it directly promotes the proliferation of AML cells by activating key signaling pathways (Akt, Erk1/2, p38, Stat3).
  • ICOSL Blockade as a Therapeutic Strategy: Blocking ICOSL signaling with an antibody in an AML mouse model significantly reduced Treg generation and slowed tumor progression, highlighting its therapeutic potential.
  • Prognostic Value of ICOS+ Tregs: The frequency of ICOS+ Tregs, more so than total Tregs or ICOSL expression on AML cells, emerged as a strong predictor of poor overall and disease-free survival in AML patients.

Key Results

  • AML patients and AML cell lines showed significantly higher mRNA expression of ICOSL compared to healthy donors.
  • TNF-α stimulation robustly increased ICOSL expression on AML cell lines.
  • Co-culture of CD4+ T cells with AML cells overexpressing ICOSL led to a significant increase in CD25+Foxp3+ Tregs and CD4+ICOS+Foxp3+ T cells.
  • ICOS+ Tregs secreted significantly more IL-10 than ICOS- Tregs.
  • IL-10 treatment dose-dependently promoted the proliferation of HL-60 and HEL AML cells, activating Akt, Erk1/2, p38, and Stat3 signaling.
  • Administration of anti-ICOSL antibody in a C1498 AML mouse model reduced Treg frequencies and retarded tumor progression.
  • High ICOSL expression on AML cells was associated with shorter disease-free survival.
  • High frequencies of both total Tregs and, more significantly, ICOS+ Tregs were associated with poorer overall and disease-free survival in AML patients.

Limitations and Future Work

  • Other Treg Inducing Factors: While ICOSL is identified as a key inducer, the authors acknowledge that other factors (e.g., TCR signals, other tumor-derived molecules like indoleamine 2,3-dioxygenase) also contribute to Treg expansion.
  • Mechanism of ICOS Costimulation Blockade: The paper notes that while blocking ICOSL reduced Tregs, further dissection of its impact on effector T cells versus Tregs is needed.
  • Clinical Translation: The authors suggest that ICOSL expression on tumor cells and the frequency of ICOS+ Tregs could serve as valuable prognostic markers. Further studies are recommended to validate these findings in larger cohorts and to explore the therapeutic potential of targeting the ICOSL/ICOS pathway. The study also calls for investigating whether ICOSL+ tumor cells are associated with increased infiltrating Tregs and poorer overall survival in a broader patient population.

Summary updated

Abstract

CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Tregs) accumulate in bone marrow microenvironment in acute myeloid leukemia (AML). However, little is known about how the tumor environment including tumor cells themselves affects this process. Here we demonstrated that AML cells expressed inducible T-cell costimulator ligand (ICOSL) that can provide costimulation through ICOS for the conversion and expansion of Tregs sustaining high Foxp3 and CD25 expression as well as a suppressive function. TNF-a stimulation up-regulated the expression of ICOSL. Furthermore, both the conversion and expansion of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells and CD4<sup>+</sup>ICOS<sup>+</sup>Foxp3<sup>+</sup> T cells were induced by co-culture with AML cells overexpressed ICOSL. CD4<sup>+</sup>CD25<sup>+</sup>ICOS<sup>+</sup> T cells possessed stronger ability to secrete IL-10 than CD4<sup>+</sup>CD25<sup>+</sup>ICOS<sup>-</sup> T cells. The mechanism by which IL-10 promoted the proliferation of AML cells was dependent on the activation of the Akt, Erk1/2, p38, and Stat3 signaling pathways. Blockade of ICOS signaling using anti-ICOSL antibody impaired the generation of Tregs and retarded the progression of an AML mice model injected with C1498 cells. The expression of ICOSL of patient AML cells and ICOS<sup>+</sup> Tregs were found to be predictors for overall survival and disease-free survival in patients with AML, with ICOS<sup>+</sup> Treg cell subset being a stronger predictor than total Tregs. These results suggest that ICOSL expression by AML cells may directly drive Treg expansion as a mechanism of immune evasion and ICOS<sup>+</sup> Treg cell frequency is a better prognostic predictor in patients with AML.
BibTeX
@inproceedings{han2018acute,
  author = {Yixiang Han and Yuqing Dong and Qianqian Yang and Wanling Xu and Songfu Jiang and Zhijie Yu and Yu Kang and Shenghui Zhang},
  title = {{Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells}},
  booktitle = {Frontiers in Immunology},
  year = {2018},
  doi = {10.3389/fimmu.2018.02227},
}
Figure